0000000000190785

AUTHOR

Giovanni Fucà

showing 3 related works from this author

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

2018

The eighth annual conference of “Innovative therapy, monoclonal antibodies, and beyond” was held in Milan on Jan. 26, 2018, and hosted by Fondazione IRCCS–Istituto Nazionale dei Tumori (Fondazione IRCCS INT). The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets, and ii) clinical translation, as well as a third session of presentations from young investigators, which focused on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies. Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor heterogeneity, with key topics addressing: 1) tumor heterogeneit…

0301 basic medicineOncologyTumor heterogeneitymedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunologyMonoclonal antibodyGeneral Biochemistry Genetics and Molecular BiologyTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyInternal medicineImmunology and AllergyMedicineAnimalbusiness.industryMicrobiotaRepertoireMelanomaImmune checkpoints inhibitionAntibodies MonoclonalImmunotherapymedicine.diseaseCancer metabolismGastrointestinal MicrobiomeRadiation therapy030104 developmental biologyCancer stemness signaling030220 oncology & carcinogenesisNeoplasmImmunotherapybusinessHumanCytokine & Growth Factor Reviews
researchProduct

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.

2021

Abstract In tumor-bearing mice, cyclic fasting or fasting-mimicking diets (FMD) enhance the activity of antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. Here we conducted a clinical trial to investigate the safety and biological effects of cyclic, five-day FMD in combination with standard antitumor therapies. In 101 patients, the FMD was safe, feasible, and resulted in a consistent decrease of blood glucose and growth factor concentration, thus recapitulating metabolic changes that mediate fasting/FMD anticancer effects in preclinical experiments. Integrated transcriptomic and deep-phenotyping analyses revealed that FMD profoundly reshapes antican…

MaleMyeloidmedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsPharmacologyTranscriptomeImmune systemmedicineCytotoxic T cellHumansProspective Studiesbusiness.industryGrowth factorCancerMetabolismFastingMiddle Agedmedicine.diseaseClinical trialmedicine.anatomical_structureTreatment OutcomeOncologyFemalebusinessColorectal NeoplasmsCancer discovery
researchProduct

Role of PD-L1 expression in triple-negative breast cancer stem cells.

2018

12081Background: Triple negative breast cancer (TNBC) is characterized by poor prognosis, lack of specific-targeted agents and is in need of new therapeutics. Immune checkpoint blockers have shown ...

Cancer ResearchPoor prognosisOncologybusiness.industryCancer researchMedicinePd l1 expressionStem cellbusinessTriple-negative breast cancerImmune checkpointJournal of Clinical Oncology
researchProduct